论文部分内容阅读
目的 研究微生态制剂对婴幼儿腹泻的临床疗效并对新近提出的一些看法与异议进行探讨。方法 186例住院的急性婴幼儿腹泻患者被随机分为思密达对照组、米雅爱儿 A治疗组、培菲康治疗组以及爱儿 A联合思密达治疗组 ,4个组的疗效以 SPSS10 .0软件包进行统计分析。结果 3个治疗组与对照组的疗效比较均无显著性差异 (P>0 .0 5 ) ,但爱儿 A的疗效优于培菲康 ,二者相比有高度显著性差异 (P<0 .0 1)。结论 爱儿 A与培菲康的疗效与思密达相当且爱儿 A的作用优于培菲康 ,爱儿 A联合思密达的疗效并不优于两种药单用。所有微生态制剂治疗的患儿均未发现任何副作用。
Objective To study the clinical efficacy of probiotics in the treatment of infantile diarrhea and to discuss some newly proposed opinions and objections. Methods A total of 186 hospitalized acute infantile diarrhea patients were randomly divided into Smecta control group, Mia Aaron A treatment group, Peifei Kang treatment group and Ailei A combined with Smecta treatment group. The efficacy of four groups SPSS10 .0 software package for statistical analysis. Results There was no significant difference in the curative effect between the three treatment groups and the control group (P> 0.05), but the therapeutic effect of Ai-Er A was better than that of Peifen Kang, with a significant difference between the two groups (P <0 .0 1). Conclusion The efficacy of Ai’er A and Pefikang is similar to that of Smecta and the effect of Ai’er A is better than that of Pefikang. The efficacy of Ai’er A and Smecta is not superior to the two drugs alone. None of the children treated with probiotics found any side effects.